Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients

International Journal of Clinical Pharmacology Research

Volumn 25, Issue 1, 2005, Pages 9-18

  Balanescu, A ^a,b   Radu, E ^a   Nat, R ^a   Regalia, T ^a   Bojinca, V ^a   Ionescu, R ^a   Balanescu, S ^a   Savu, C ^a   Predeteanu, D ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b St Maria Hospital   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

CD123 ANTIGEN; CD83 ANTIGEN; GLYCOPROTEIN P 15095; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; FLOW CYTOMETRY; HUMAN; LUNG TUBERCULOSIS; PHENOTYPE; RHEUMATOID ARTHRITIS; VENOUS BLOOD;

EID: 17644426014     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Roitt I., Brostoff J., Male D. "Immunology." Vol. 1. Mosby, London, 2001, p. 480.
2. Pettit A., Thomas R. Dendritic cells: The driving force behind autoimmunity in rheumatoid arthritis. Immun. Cell Biol., 77, 420, 1999.
3. Larsen C., Ritchie S., Hendrix R. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol., 152, 5208, 1994.
4. Santiago-Schwarz F., Anand P., Liu S., Carsons S. Dendritic cells in rheumatoid arthritis: Progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate Th1 inflammatory-type responses. J. Immunol., 167, 1758, 2001.
5. Quaratino S., Duddy L., Londei M. Fully competent dendritic cells as inducers of T cell anergy in autoimmunity. Proc. Natl. Acad. Sci., 97, 10911, 2000.
6. Robertson S., Young S., Viner N., Bacon P. Enhanced costimulatory ability of synovial fluid accessory cells in rheumatoid arthritis. Br. J. Rheumatol., 36, 413, 1997.
7. Tak P., Smeets T., Daha M. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum., 40, 217, 1997.
8. Banchereau J., Briere F., Caux C., Davoust J. Immunobiology of dendritic cells. Ann. Rev. Immunol., 18, 767, 2000.
9. Abbas A., Lichtman A. "Cellular and Molecular Immunology." Vol. 1: Saunders, Philadelphia, 2003, p. 562.
10. Balsa A. Differential expression of the co-stimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid ST. Br. J. Rheumatol., 35, 33, 1996.
11. Nakajima A. Manipulation of co-stimulatory pathways in autoimmune diseases. Mod. Rheumatol., 11, 184, 2001.
12. Steiner G., Tohidast-Akrad M., Witzmann G. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology, 38, 202, 1999.
13. Bresnihan B. Pathogenesisi of joint damage in rheumatoid arthritis. J. Rheumatol., 26, 717, 1999.
14. Lam J., Abu-Amer Y., Nelson C., Ross R., Teitelbaum S. Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann. Rhem. Dis., 61(Suppl. II), 82, 2002.
15. Thomas R., MacDonald K., Pettit A., Cavanagh L., Padmanabha J., Zehntner S. Dendritic cells and the pathogenesis of rheumatoid arthritis. J. Leukoc. Biol., 66, 286, 1999.
16. Jones R., Moreland L. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull. Rheum. Dis., 48(3), 1, 1999.
17. Klippel J. Biological therapy for rheumatoid arthritis. N. Engl. J. Med., 343, 1640, 2000.
18. den Broeder A., Joosten L., Saxne T., et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis., 61, 311, 2002.
19. Marinova-Mutafchieva L., Williams R., Mauri C. A comparative study into the mechanism of action of anti-TNF, anti-CD4 and combined anti-TNF/anti-CD4 treatment in early collagen-induced arthritis. Arthritis Rheum., 43(3), 638, 2000.
20. Pittoni V., Bombardieri M., Spinelli F., et al. Anti-tumour necrosis factor alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann. Rheum. Dis., 61, 723, 2002.
21. Pisetsky D. Tumor necrosis factor blockers in rheumatoid arthritis. N. Engl. J. Med., 342, 810, 2000.
22. Balanescu A., Radu E., Nat R., et al. Co-stimulatory and adhesion molecules of dendritic cells in rheumatoid arthritis. J. Cell Mol. Med., 6(3), 415, 2002.
23. van Riel P., van Gestel A., Scott D. "EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis". Van Zuiden, The Netherlands, 2000, pp. 10-15.
24. Den Breeder A., Creemers M., van Gestel A., van Riel P. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α. Rheumatology (Oxford), 41, 638, 2002.
25. Firestein G. Rheumatoid synovitis and pannus. In: Klippel J., Dieppe P. (Eds.). "Rheumatology." Vol. 1. Mosby, London, 1998, pp.5.13.5-5.13.6.
26. Kraan M. Immunohistological analysis of ST for differential diagnosis in early arthritis. Rheumatology, 29, 1074, 1999.
27. Klimiuk P., Sierakowski S., Latosiewicz R., et al. Circulating tumour necrosis factor α and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann. Rheum. Dis., 62(5), 472, 2003.
28. Kraan M., Haringman J., Weedon H., et al. T cell, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann. Rheum. Dis., 63(5), 483, 2004.
29. Pettit A., Ahern M., Zehntner S., Smith M., Thomas R. Comparison of differentiated dendritic cell infiltration of autoimmune and osteoarthritis synovial tissue. Arthritis Rheum., 44, 105, 2001.
30. Radstake T., van Lent P., Pesman G., et al. High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcγR triggering. Ann. Rheum. Dis., 63(6), 696, 2004.
31. Thomas R., Lipsky P. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursors and mature APC. J. Immunol., 153, 4016, 1994.
32. Flores-Romo L. In vivo maturation and migration of dendritic cells. Immunology, 102, 255, 2001.
33. Tak P., Taylor P., Breedveld F. Decrease in cellularity and expression of adhesion molecules by anti-TNF alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum., 39, 1077, 1996.
34. Smeets T., Kraan M., van Loon E., Tak P. Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum., 48(8), 2155, 2003.
35. Taylor P., Peters A., Paleolog E., Chapman P., Elliott M., McCloskey R. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum., 43, 38, 2000.
36. Goedkoop A., Kraan M., Teunissen M., et al. Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 63(7), 769, 2004.
37. Charles P., Elliott M., Davis D., Potter A., Kalden J., Antoni C. Regulation of cytokines, cytokines inhibitors and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J. Immunol., 163, 1521, 1999.
38. Dolhain R., Tak P., Dijkmans B., De Kuiper R, Breedveld F., Miltenburg A. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br. J. Rheumatol., 37, 502, 1998.
39. Kraan M., Reece R., Barg E., Smeets T., Farnell J., Rosenburg R. Modulation of inflammation and metalloproteinase expression in synovial tissue by methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum., 43, 1820, 2000.
40. Pettit A., Weedon H., Ahern M., et al. Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis. Rheumatology, 40, 1243, 2001.
41. Smeets T., Dayer J., Kraan M. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum., 43, 270, 2000.
42. Kraan M., Smeets T., van Loon M., Breedveld F., Dijkmans B., Tak P. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann. Rheum. Dis., 63(9), 1056, 2004.
43. Youssef P., Triantafillou S., Parker A., Coleman M., Roberts-Thomson R, Ahern M. Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis: Reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum., 39, 1970, 1996.
44. Youssef P., Haynes D., Triantafillou S., Parker A. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid and synovial membrane in rheumatoid arthritis. Arthritis Rheum., 40, 1400, 1997.
45. Nissinen R., Leirisalo-Repo M., Peltomaa R., Palosuo T., Vaaralo O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann. Rheum. Dis., 63(6), 681, 2004.
46. Elliott M., Maini R., Feldmann M., Kalden J., Antoni C., Smolen J. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α(cA2) versus placebo in rheumatoid arthritis. Lancet, 344, 1105, 1994.
47. Lipsky P., van der Heijde D., St. Clair E., Furst D., Breedveld F., Kalden J. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trials in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med., 343, 1594, 2000.
48. Durez P., Nzeusseu Toukap A., Lauwerys B., et al. A randomized comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann. Rheum. Dis., 63(9), 1069, 2004.